Menu
This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Identifying Lewy Body pathology at the MCI stage allows for a more personalized approach to disease management.
Ongoing studies indicate the need for early diagnosis and better definition of AD sub-types.
“Our results support a role for α-synuclein even in MCI, the early phase of AD, in addition to being a potential contributor in MCI and AD diagnosis or monitoring of disease progression.” (Ref.6)
“RT-QuIC (a research version of SAA) “identified patients with MCI-LB against cognitively unimpaired controls with 95% sensitivity, 97% specificity, and 96% accuracy and showed 98% specificity in neuropathologic controls.” (Ref.11)
Download the SYNTap Test Specification Sheet for details.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
Amprion has some important news we need to share with you!
To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.
Old self-pay price: $1500.00. New self-pay price: $995.00
Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process
